12:59 , Apr 30, 2019 |  BC Innovations  |  Distillery Therapeutics

RUNX1, RUNX3, CBFB and PMP22 as targets for neurofibromatosis

DISEASE CATEGORY: Cancer INDICATION: Neurofibromatosis Cell culture and mouse studies suggest promoting PMP22 expression, dual RUNX1/RUNX3 inhibition, or inhibiting the interactions of CBFB with RUNX1 and RUNX3 could help treat neurofibromatosis. In mouse neurofibroma Schwann...
07:00 , Apr 16, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Histone deacetylase (HDAC); runt-related transcription factor 3 (RUNX3)

Cancer INDICATION: Cancer; solid tumors In vitro and rodent studies suggest HDAC inhibitors that activate the tumor suppressor RUNX3 could help treat cancer. Chemical synthesis and testing in an HDAC inhibition-induced RUNX3 activation assay of...